Epizyme reported its fourth quarter and full year 2020 financial results, revealing a net revenue increase of 31% for TAZVERIK, reaching $4.5 million in Q4. Despite operational challenges from COVID-19, new prescribing accounts grew by over 50%. Total revenue for 2020 was $15.8 million, down from $23.8 million in 2019. Operating expenses rose significantly, resulting in a net loss of $66.2 million for Q4. Epizyme expects its cash runway to extend into 2023, with adjusted operating expenses projected between $235 and $255 million for 2021.
Epizyme (Nasdaq: EPZM) announced a conference call on February 23, 2021, to discuss its fourth quarter and full year 2020 financial results. The call will start at 8:00 a.m. ET. Additionally, the company will participate in the Cowen and Company's 41st Annual Healthcare Conference on March 4, 2021, and the Barclays Global Healthcare Conference on March 9, 2021. TAZVERIK (tazemetostat), the company's FDA-approved product, treats specific cancers and remains in clinical trials for other applications. Live webcasts will be accessible on Epizyme's website.
Epizyme, a commercial-stage biopharmaceutical company (Nasdaq: EPZM), announced that CEO Robert Bazemore will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 12:35 p.m. ET. A live webcast will be available on the company's investor website, archived for 60 days.
Epizyme focuses on developing novel epigenetic therapies, with TAZVERIK® approved for specific cancer types. The company aims to match innovative treatments with genetic drivers of diseases, enhancing patient care.
Epizyme (Nasdaq: EPZM) reported Q3 2020 financial results, highlighting a 55% revenue increase to $3.4 million driven by TAZVERIK's FDA approval in Follicular Lymphoma. Despite challenges from COVID-19 on patient access, new prescriptions for TAZVERIK grew month-over-month. The company holds $279.9 million in cash as of Sep 30, 2020, and anticipates funding operations through at least 2023 following an expanded loan agreement. Operating expenses were reduced, with an updated guidance of $215 million to $235 million for the year.
Epizyme (NASDAQ: EPZM) announced an amended agreement with Pharmakon Advisors to expand its loan facility, drawing down $150 million. This follows a previous $70 million draw for regulatory milestones linked to TAZVERIK's FDA approvals. The expanded financing aims to bolster the company's balance sheet and support critical growth initiatives, including TAZVERIK's commercial execution and ongoing development. Epizyme believes its current cash resources will sustain operations through at least 2023, reducing the need for additional financing soon.
Epizyme (Nasdaq: EPZM) announced a conference call and webcast to discuss its Q3 2020 financial results on November 6, 2020, at 8:00 a.m. ET. The call will provide insights into the company's performance and strategic direction. Epizyme is a commercial-stage biopharmaceutical firm focusing on novel epigenetic therapies, having one FDA-approved product, TAZVERIK®, for specific cancer treatments. The drug has accelerated approval based on overall response rates, but continued approval may depend on further confirmation of clinical benefits.
Epizyme (Nasdaq: EPZM) announced the publication of results from its Phase 2 trials of TAZVERIK (tazemetostat) in epithelioid sarcoma and relapsed/refractory follicular lymphoma in The Lancet Oncology. These results support the accelerated FDA approvals granted in January and June 2020. The trials showed durable clinical responses and a favorable safety profile. The company aims to expand TAZVERIK's application to more cancers, highlighting its potential as a first-in-class treatment.